Singapore-Based CytoMed Therapeutics Stock Dips After SunAct Joins Clinical Trial As Joint Sponsor

On Monday, CytoMed Therapeutics (NASDAQ:GDTC) stock is down 6.35% at $3.23 at last check Monday.

The Singapore-based clinical-stage biopharmaceutical entered into a five-year Business & Research Collaboration Agreement (BRCA) with India-based SunAct Cancer Institute Private.

The BRCA will explore the safety, tolerability, potency, and efficacy of CytoMed’s proprietary allogeneic gamma delta T cells for various cancers (including solid tumors). The human clinical research trial includes a Phase 2 investigator-initiated trial in India.

CytoMed and SunAct will be the joint sponsors of the clinical trial.

“Initiating this research and undertaking the accelerated Clinical Trial in the form of a combined Phase 1 and Phase 2 Clinical Trial targets not just the safety and efficacy of the therapeutic application and intervention of allogeneic gamma delta T Cells in the treatment of solid cancers but also expedites the gathering of information and data on the initial safety, preliminary efficacy and optimal dosing. We expect to identify the types of cancers the therapy will work for, including the side effects of the same if any and how we might manage them,” said Dr Vijay Patil.

CytoMed chairman Peter Choo called the collaboration with SunAct “timely.”

According to the BRCA, CytoMed will provide scientific and technical assistance in planning and conducting the clinical trial.

CytoMed will also be responsible for manufacturing the allogeneic gamma delta T cells as the investigational product.

Read Next:

• ArcelorMittal South Africa To Cut 3,500 Jobs Amid Economic Struggles

Image: Shutterstock